Hansa Biopharma Says Co's Biologics License Application (BLA) For Imlifidase Accepted By The FDA
ReutersFeb 18, 2026 6:55 PM
Feb 18 (Reuters) - Hansa Biopharma AB HNSA.ST:
HANSA BIOPHARMA'S BIOLOGICS LICENSE APPLICATION (BLA) FOR IMLIFIDASE ACCEPTED BY THE FDA
HANSA BIOPHARMA AB - TRIAL MET PRIMARY ENDPOINT WITH IMPROVED KIDNEY FUNCTION
HANSA BIOPHARMA AB - A KEY SECONDARY ENDPOINT-DIALYSIS INDEPENDENCE AT 12 MONTHS-WAS ALSO STATISTICALLY SIGNIFICANT IN FAVOR OF IMLIFIDASE
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.
Related Articles
Eurozone Inflation Gradually Recedes Will ECB Rate-Cut Window Open Again? 2026 Euro Exchange Rate Trend Forecast
TradingKey - After enduring three consecutive years of "high prices, high interest rates, high debt, and low growth," the Eurozone economy is finally demonstrating resilience through a moderate recovery. Currently, the European Central Bank (ECB) faces the ultimate test of maintaining the status quo versus implementing "preemptive rate cuts." Euro exchange rate volatility, inflation trends, and the economic outlook have become the primary focus for investors and financial enthusiasts when allocating overseas assets and capitalizing on currency opportunities.TradingKey
13 hours ago
AMD Stock Price Prediction 2030: Can AMD Narrow Nvidia’s AI Lead?
TradingKey - In the past couple of years, the semiconductor industry has experienced a major change. One question that investors still have is whether or not AMD (AMD) will be able to keep up with Nvidia (NVDA) as far as AI is concerned. What is the possible future of AMD's stock through 2026 and beTradingKey
17 hours ago
Bitcoin Price Prediction 2029-2035: Institutional Accumulation and the U.S. Treasury’s Strategic Reserve Pivot
Explore the 2026 Bitcoin landscape: From the U.S. Strategic Reserve and Michael Saylor’s $75B war chest to Cathie Wood’s 2030 forecast. Is BTC the new Digital Gold?TradingKey
Fri, Feb 13
